Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI:10.2217/pme-2020-0172

Alma Faviola Favela-Mendoza, Brenda Guadalupe Rodríguez-Rodríguez, Eduardo Rojas-Prado, Mariana Chávez-Arreguin, José Alonso Aguilar-Velázquez, Gabriela Martínez-Cortés, Héctor Rangel-Villalobos

{"title":"Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations.","authors":"Alma Faviola Favela-Mendoza, Brenda Guadalupe Rodríguez-Rodríguez, Eduardo Rojas-Prado, Mariana Chávez-Arreguin, José Alonso Aguilar-Velázquez, Gabriela Martínez-Cortés, Héctor Rangel-Villalobos","doi":"10.2217/pme-2020-0172","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the genetic distribution of the rs4149056 and rs2306283 variants in the SLCO1B1 gene in Mexican Mestizo (admixed) and Native American groups. Materials & methods: We recruited 360 volunteers who were qPCR-genotyped with TaqMan probes. Results: Allele and genotype frequencies are reported. Among the expected rs4149056-rs2306283 haplotypes, T-A (42.35-58.47%) was the most prevalent which relates to the normal activity of the OATP1B1 transporter. This was followed by the T-G haplotype associated with further statin transport and cholesterol reduction (32.49-43.76%). Conclusion: Based on these SLCO1B1 gene variants, we confirmed that a minimum fraction of the Mexican study populations would be at risk from decreasing simvastatin transport and the development of statin-induced myopathy.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"533-540"},"PeriodicalIF":1.7000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2020-0172","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the genetic distribution of the rs4149056 and rs2306283 variants in the SLCO1B1 gene in Mexican Mestizo (admixed) and Native American groups. Materials & methods: We recruited 360 volunteers who were qPCR-genotyped with TaqMan probes. Results: Allele and genotype frequencies are reported. Among the expected rs4149056-rs2306283 haplotypes, T-A (42.35-58.47%) was the most prevalent which relates to the normal activity of the OATP1B1 transporter. This was followed by the T-G haplotype associated with further statin transport and cholesterol reduction (32.49-43.76%). Conclusion: Based on these SLCO1B1 gene variants, we confirmed that a minimum fraction of the Mexican study populations would be at risk from decreasing simvastatin transport and the development of statin-induced myopathy.

查看原文本刊更多论文

SLCO1B1基因他汀类转运保护性单倍型在墨西哥人群中的患病率。

目的:探讨墨西哥混血儿和美洲原住民SLCO1B1基因rs4149056和rs2306283变异的遗传分布。材料与方法:我们招募了360名志愿者，使用TaqMan探针进行qpcr基因分型。结果:报告了等位基因和基因型频率。在预期的rs4149056-rs2306283单倍型中，T-A(42.35-58.47%)最为普遍，这与OATP1B1转运体的正常活性有关。其次是与他汀类药物转运和胆固醇降低相关的T-G单倍型(32.49% -43.76%)。结论:基于这些SLCO1B1基因变异，我们证实了墨西哥研究人群中最小比例的辛伐他汀转运减少和他汀诱导肌病发展的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.